Medical device company profile

EBAMed

Swiss device developer building ultrasound-based cardiac motion tracking and beam guidance for non-invasive cardiac radioablation.

Medical Device Manufacturer and DeveloperCardiovascular & VascularElectrophysiology

Headquarters🇨🇭Geneva, Switzerland

Founded2018

Commercial statusIn developmentInvestigational CardioKit guidance technology; not CE-marked or FDA-cleared and not available for sale.

Employees11–50 ^[6]LinkedIn company-size range · Checked 2026-11-04

Estimated revenueNot confirmed

Disclosed funding€14.35 million ^[5]Series A announced by investor OCCIDENT in June 2023; dated round disclosure.

Official websiteeba-med.com ↗

Company overview

EBAMed is a Geneva, Switzerland medical device company developing guidance technology for non-invasive cardiac radioablation. Founded in 2018, it is led by CEO Marcin Gołębicki, with co-founder Adriano Garonna serving as Chief Technology Officer.

Its CardioKit platform uses ultrasound to track cardiac motion caused by the heartbeat and breathing. The system is designed to coordinate an external radiation beam with a moving cardiac target; it provides motion information and beam gating rather than generating the treatment beam itself.

The development programme focuses on enabling radiation-based treatment of arrhythmias and includes research into monitoring cardiac motion during cancer radiotherapy. CardioKit is investigational, is not CE-marked or FDA-cleared, and is not available for sale. Human imaging feasibility work and preclinical studies form part of the evidence base ahead of therapeutic trials.

^{[1][2][3][4][5][6]}

Leadership

5 people

Marcin GołębickiChief Executive Officer ^[2]

Adriano GaronnaCo-founder & Chief Technology Officer ^[2]

Chiara BonaciniFinance Controller & Corporate Affairs ^[2]

Tiziana MarottaClinical Research Director ^[2]

Olivier CoquozHead of R&D ^[2]

Products & regulatory status How does MedTechIndex get this information?

Summary

EBAMed identifies CardioKit as investigational technology that is not CE-marked or FDA-cleared and is not available for sale. The system is being developed to supply ultrasound-based cardiac tracking and beam-gating information to a radiotherapy workflow. ^[1][3]

The company’s evidence includes preclinical research and human imaging feasibility work. Those studies support investigation of motion tracking; they do not establish therapeutic effectiveness for arrhythmia treatment or a cleared cancer-radiotherapy indication. ^[4][1]

Regulatory snapshot How to read this snapshot

U.S. FDA

—
510(k) clearances: —
De Novo grants: —
PMA approvals: —
Recall events

Latest recorded source review: 2026-11-04.

Scope: selected product families.

Commercial portfolio snapshot

No commercially marketed product portfolio has been established in the reviewed material.

Commercial development

Ultrasound cardiac motion tracking and beam-gating system

CardioKit ↗

Investigational guidance platform designed to track cardiac motion with ultrasound and synchronize external radiation delivery with a moving target. It is intended to integrate with radiotherapy equipment rather than deliver radiation itself. ^[3]

Investigational · Not available for sale